The Potential Protective Effect of Using Muscle Relaxants During Electroporation Ablation (PFA)
Recruiting · NCT06707532 · Interventional (participants receive a specific treatment) · Lead sponsor: 4th Military Clinical Hospital with Polyclinic, Poland
View the official record on ClinicalTrials.gov →Interventions studied
PropofolRocuronium
What this trial is about
The study aims to improve the safety of the electroporation ablation (PFA) procedure by using muscle relaxants to reduce skeletal muscle damage during the procedure. It will also assess myocardial damage to improve the procedure's quality and speed up recovery after the procedure.
Who can take part
Age range
18 Years to 90 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Patients with requirement for PFA ablation for cardiac indications and ability to provide informed consent for study participation
Exclusion criteria
- Patients with allergies to the general anaesthetics used, genetic diseases of the neuromuscular plateau - e.g. Duchenne dystrophy, myasthenia gravis - and patients who do not gived informed consent to participate in the study will be excluded from the study.
Where it is running
1 location listed.
- 4th Military Clinical Hospital with Polyclinic - Wroclaw, Lower Silesian Voivodeship, Poland